Blue Water Acquisition Corp. IV quarterly report, Q3 FY2026

Blue Water Acquisition Corp. IV — Form 10-Q Summary

Reporting period: Quarter and nine months ended September 30, 2026; filed November 16, 2026. The company is a Cayman Islands blank-check company (SPAC), formed to complete a business combination. It has not selected a target or begun substantive target discussions and has no operating revenue.

Financial Results and Position

MetricThree months ended September 30, 2026Nine months ended September 30, 2026
Operating revenueNoneNone
Operating expenses / operating loss$294,180$913,786
Trust-account income$1,183,576$2,428,429
Other income from over-allotment optionNone$106,000
Net income$889,396$1,620,643
Net income (loss) per redeemable Class A share$0.07$0.50
Net income (loss) per non-redeemable Class A and Class B share($0.02)($0.63)
  • Net income reflects trust interest, not operating performance. For the nine-month period, reported income also included a $51,000 fair-value gain and $55,000 gain on extinguishment of the over-allotment option liability.
  • Cash used in operating activities was $1,056,127 for the nine months. Investing cash outflow of $130.0 million to fund the trust was offset by $131.1 million of financing cash inflow. The company reported no cash or cash equivalents at September 30.
  • Total assets were $132,767,194, including $132,428,429 held in the trust account and $243,444 due from a related party, net. Working capital was $240,402, versus a deficit of $181,480 at December 31, 2025.
  • Total liabilities were $4,617,953, including a $4,550,000 deferred underwriter fee payable only upon a completed business combination. No promissory note or working-capital loans were outstanding at quarter-end.
  • Operating margins are not meaningful because the company has no operating revenue. The comparable 2025 period was inception through September 30, 2025, when the company reported a $72,147 net loss; it is not a comparable full quarter or nine-month period.

Material Changes and Business Developments

  • The company completed its IPO on March 23, 2026, issuing 13.0 million units at $10 each for $130.0 million gross proceeds. It also sold 425,000 private-placement units for $4.25 million. The trust held $132.4 million at quarter-end.
  • The underwriters partially exercised their over-allotment option for 500,000 units; the remaining option expired May 3, 2026, and 458,333 founder shares were forfeited.
  • At September 30, 2026, 13.0 million public Class A shares were subject to possible redemption; the company also had 425,000 non-redeemable Class A shares and 4,333,334 Class B shares outstanding. As of November 16, total Class A shares issued and outstanding, inclusive of shares in units, were 13,425,000.
  • The trust funds are intended to support a business combination. The company has 21 months from the March 23, 2026 IPO closing to complete one, subject to any permitted amendment to the completion period.

Outlook, Risks, and Other Notable Items

  • Management expects ongoing public-company and target-search costs. It states that the company lacks resources to sustain operations for a year and that these conditions raise substantial doubt about its ability to continue as a going concern. The sponsor may provide working-capital loans but is not obligated to do so; no assurance is given that a business combination or additional funding will be achieved.
  • The company expects to focus on biotechnology, healthcare, and technology, but may pursue targets in any industry. A business combination requires a target or targets meeting the filing’s stated 80% fair-market-value test and the company to obtain control.
  • Public shareholders may redeem shares in connection with a business combination or certain charter amendments. If no combination is completed within the completion window, public shares are to be redeemed, subject to applicable law and creditor claims. The $4.55 million deferred underwriting fee is payable upon a completed combination.
  • Potential combination financing through new equity or debt could dilute existing holders, alter voting control, impose debt-service and covenant burdens, or affect share and warrant prices. Warrants have an $11.50 exercise price and may expire worthless if registration or other exercise conditions are not met.
  • The filing cites geopolitical conflict, sanctions, trade restrictions, shipping disruption, commodity and market volatility, and related compliance risks as factors that could impede a business combination. The sponsor’s trust indemnity is limited, and the company has not verified the sponsor’s ability to meet it.
  • Disclosure controls and procedures were deemed ineffective at September 30 due to a material weakness in the design, implementation, and operation of controls. Management plans remediation, but timing and effectiveness are uncertain.
  • The company reported no material pending litigation and no subsequent events requiring adjustment or disclosure.

Key Facts for Investors to Verify

  • Whether management identifies a target, obtains committed financing, and completes a transaction within the applicable deadline.
  • The availability and accessibility of the $243,444 net related-party receivable: company cash was held in a sponsor bank account, offset by amounts owed to related parties.
  • Trust-account balance, redemption value per public share, and the treatment of the deferred underwriting fee and creditor claims as a transaction or liquidation approaches.
  • Progress and effectiveness of remediation for the disclosed material weakness in disclosure controls.
  • Potential dilution from founder-share conversion adjustments, new securities, warrants, or any convertible working-capital loans.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.